[go: up one dir, main page]

FI963496L - Farmaseuttinen täyteaine, jolla on parempi puristettavuus - Google Patents

Farmaseuttinen täyteaine, jolla on parempi puristettavuus Download PDF

Info

Publication number
FI963496L
FI963496L FI963496A FI963496A FI963496L FI 963496 L FI963496 L FI 963496L FI 963496 A FI963496 A FI 963496A FI 963496 A FI963496 A FI 963496A FI 963496 L FI963496 L FI 963496L
Authority
FI
Finland
Prior art keywords
improved compressibility
pharmaceutical filler
filler
pharmaceutical
compressibility
Prior art date
Application number
FI963496A
Other languages
English (en)
Swedish (sv)
Other versions
FI963496A7 (fi
FI963496A0 (fi
Inventor
John N Staniforth
Bob E Sherwood
Edward A Hunter
Original Assignee
Mendell Co Inc Edward
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/370,576 external-priority patent/US5585115A/en
Application filed by Mendell Co Inc Edward filed Critical Mendell Co Inc Edward
Publication of FI963496A0 publication Critical patent/FI963496A0/fi
Publication of FI963496A7 publication Critical patent/FI963496A7/fi
Publication of FI963496L publication Critical patent/FI963496L/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/2036—Silicones; Polysiloxanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Colloid Chemistry (AREA)
FI963496A 1995-01-09 1996-01-05 Farmaseuttinen täyteaine, jolla on parempi puristettavuus FI963496L (fi)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/370,576 US5585115A (en) 1995-01-09 1995-01-09 Pharmaceutical excipient having improved compressability
US08/486,183 US5725883A (en) 1995-01-09 1995-06-07 Pharmaceutical excipient having improved compressibility
PCT/US1996/000539 WO1996022080A1 (en) 1995-01-09 1996-01-05 Pharmaceutical excipient having improved compressibility

Publications (3)

Publication Number Publication Date
FI963496A0 FI963496A0 (fi) 1996-09-06
FI963496A7 FI963496A7 (fi) 1996-11-06
FI963496L true FI963496L (fi) 1996-11-06

Family

ID=27005010

Family Applications (1)

Application Number Title Priority Date Filing Date
FI963496A FI963496L (fi) 1995-01-09 1996-01-05 Farmaseuttinen täyteaine, jolla on parempi puristettavuus

Country Status (12)

Country Link
US (3) US5866166A (fi)
EP (1) EP0749300B1 (fi)
JP (1) JP3728321B2 (fi)
AU (1) AU708346B2 (fi)
BR (1) BR9605245A (fi)
CA (1) CA2183882C (fi)
FI (1) FI963496L (fi)
HU (1) HUP9602361A3 (fi)
IL (3) IL139728A (fi)
NO (1) NO321771B1 (fi)
TW (1) TW505529B (fi)
WO (1) WO1996022080A1 (fi)

Families Citing this family (189)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6440457B1 (en) * 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
GB9407386D0 (en) 1994-04-14 1994-06-08 Smithkline Beecham Plc Pharmaceutical formulation
US6106865A (en) * 1995-01-09 2000-08-22 Edward Mendell Co., Inc. Pharmaceutical excipient having improved compressibility
US6936277B2 (en) * 1995-01-09 2005-08-30 J. Rettenmaier & Soehne Gmbh & Co. Kg Pharmaceutical excipient having improved compressibility
US5948438A (en) * 1995-01-09 1999-09-07 Edward Mendell Co., Inc. Pharmaceutical formulations having improved disintegration and/or absorptivity
US6395303B1 (en) * 1996-06-10 2002-05-28 Edward Mendell Co., Inc. Process for preparing a directly compressible solid dosage form containing microcrystalline cellulose
US5585115A (en) * 1995-01-09 1996-12-17 Edward H. Mendell Co., Inc. Pharmaceutical excipient having improved compressability
DE29502547U1 (de) * 1995-02-16 1995-03-30 Röhm GmbH, 64293 Darmstadt Thermoplastisches Überzugs- und Bindemittel für Arzneiformen
US20030109503A1 (en) * 1995-06-06 2003-06-12 Smithkline Beecham P.L.C. Pharmaceutical formulations comprising clavulanic acid alone or in combination with other beta-lactam antibiotics
CN1089235C (zh) * 1995-07-21 2002-08-21 第一制药株式会社 颗粒制剂和其制备方法
TW487582B (en) * 1995-08-11 2002-05-21 Nissan Chemical Ind Ltd Method for converting sparingly water-soluble medical substance to amorphous state
SE9604124D0 (sv) * 1996-11-12 1996-11-12 Pharmacia & Upjohn Ab Compact member, method of manufacturing and use thereof
US6949264B1 (en) 1996-11-27 2005-09-27 Wm. Wrigley Jr. Company Nutraceuticals or nutritional supplements and method of making
US20030124187A1 (en) * 1997-02-14 2003-07-03 Smithkline Beecham Laboratoires Pharmaceutiques, Pharmaceutical formulations comprising amoxycillin and clavulanate
FR2761266B1 (fr) * 1997-03-28 1999-07-02 Sanofi Sa Composition pharmaceutique formee par granulation humide pour l'administration orale d'un derive du n-piperidino-3- pyrazolecarboxamide, de ses sels et de leurs solvates
US6531154B1 (en) * 1997-06-10 2003-03-11 Brown University Research Foundation Modulated release from biocompatible polymers
NZ328751A (en) * 1997-09-16 1999-01-28 Bernard Charles Sherman Solid medicament containing an anionic surfactant and cyclosporin
IN186245B (fi) 1997-09-19 2001-07-14 Ranbaxy Lab Ltd
US6066339A (en) * 1997-10-17 2000-05-23 Elan Corporation, Plc Oral morphine multiparticulate formulation
GB9724186D0 (en) 1997-11-14 1998-01-14 British Tech Group Low temperature coatings
US6337090B1 (en) * 1997-12-22 2002-01-08 Schering Corporation Orally administrable solid ribavirin dosage forms and process for making them
US6919372B1 (en) * 1997-12-26 2005-07-19 Yamanouchi Pharmaceutical Co., Ltd. Sustained release pharmaceutical compositions
JP4533531B2 (ja) * 1998-04-03 2010-09-01 ビーエム リサーチ エイ／エス 制御放出組成物
US6232351B1 (en) * 1998-05-22 2001-05-15 Amway Corporation Co-processed botanical plant composition
US7087577B2 (en) * 1998-10-16 2006-08-08 Zimmer Orthobiologies, Inc. Method of promoting natural bypass
US6992066B2 (en) * 1998-10-16 2006-01-31 Zimmer Orthobiologics, Inc. Povidone-containing carriers for polypeptide growth factors
EP1137403B1 (en) 1998-12-11 2009-03-11 Nostrum Pharmaceuticals, Inc. Sustained release tablet containing hydrocolloid and cellulose ether
US7163705B2 (en) * 1998-12-15 2007-01-16 Wm. Wrigley Jr. Company Coated chewing gum product and method of making
US6627234B1 (en) 1998-12-15 2003-09-30 Wm. Wrigley Jr. Company Method of producing active agent coated chewing gum products
US6531114B1 (en) 1999-04-06 2003-03-11 Wm. Wrigley Jr. Company Sildenafil citrate chewing gum formulations and methods of using the same
US6586023B1 (en) 1998-12-15 2003-07-01 Wm. Wrigley Jr. Company Process for controlling release of active agents from a chewing gum coating and product thereof
DE19913606A1 (de) * 1999-03-25 2000-09-28 Basf Ag Pulverförmige Solubilisationshilfsstoffe für feste pharmazeutische Darreichungsformen
IT1305308B1 (it) * 1999-03-26 2001-05-04 Biosint S P A Granulato ad alto contenuto di l-carnitina o alcanoil-l-carnitina,particolarmente adatto alla produzione di compresse per compressione
US6322806B1 (en) 1999-04-06 2001-11-27 Wm. Wrigley Jr. Company Over-coated chewing gum formulations including tableted center
US6773716B2 (en) 1999-04-06 2004-08-10 Wm. Wrigley Jr. Company Over-coated chewing gum formulations
US7935362B2 (en) * 1999-04-06 2011-05-03 Wm. Wrigley Jr. Company Over-coated product including consumable center and medicament
AU784112B2 (en) * 1999-04-06 2006-02-09 Wm. Wrigley Jr. Company Pharmaceutical chewing gum formulations
US6426090B1 (en) * 1999-04-06 2002-07-30 Wm. Wrigley Jr. Company Over-coated product including tableted center and medicament
US20020159956A1 (en) * 1999-04-06 2002-10-31 Ream Ronald L. Over-coated chewing gum formulations
US6355265B1 (en) 1999-04-06 2002-03-12 Wm. Wrigley Jr. Company Over-coated chewing gum formulations
US6294199B1 (en) 1999-04-13 2001-09-25 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising administering amoxycillin
US7250176B1 (en) * 1999-04-13 2007-07-31 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection
US6878386B1 (en) 1999-04-13 2005-04-12 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising amoxycillin and potassium clavulanate
FR2794762B1 (fr) 1999-06-14 2002-06-21 Centre Nat Rech Scient Dispersion de microfibrilles et/ou de microcristaux, notamment de cellulose, dans un solvant organique
EP1183014B1 (en) 1999-06-14 2003-10-08 Cosmo S.p.A. Controlled release and taste masking oral pharmaceutical compositions
US8895064B2 (en) 1999-06-14 2014-11-25 Cosmo Technologies Limited Controlled release and taste masking oral pharmaceutical composition
EP1064938A1 (en) * 1999-06-28 2001-01-03 Sanofi-Synthelabo Pharmaceutical dosage forms for controlled release producing at least a timed pulse
US20040258750A1 (en) * 1999-06-28 2004-12-23 Gerard Alaux Timed dual release dosage forms comprising a short acting hypnotic or a salt thereof
US6264973B1 (en) * 1999-08-26 2001-07-24 Fei Enterprises, Ltd. Apparatus and method for anesthetizing the cervical region of a female
US6541048B2 (en) 1999-09-02 2003-04-01 Wm. Wrigley Jr. Company Coated chewing gum products containing an acid blocker and process of preparing
US6569472B1 (en) 2000-09-01 2003-05-27 Wm. Wrigley Jr. Company Coated chewing gum products containing antacid and method of making
US6645535B2 (en) 1999-09-02 2003-11-11 Wm. Wrigley Jr. Company Method of making coated chewing gum products containing various antacids
US6663849B1 (en) 2000-09-01 2003-12-16 Wm. Wrigley Jr. Company Antacid chewing gum products coated with high viscosity materials
US9253991B2 (en) 1999-09-20 2016-02-09 Jack Barreca Chewing gum with B vitamins
US9387168B2 (en) 1999-09-20 2016-07-12 Jack Barreca Chewing gum with tomatidine
AU3885201A (en) * 1999-09-20 2001-04-24 Mastercare Diet and weight control gum and sucker
GB9925127D0 (en) * 1999-10-22 1999-12-22 Pharmacia & Upjohn Spa Oral formulations for anti-tumor compounds
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
RU2230556C2 (ru) 1999-10-29 2004-06-20 Эро-Селтик, С.А. Препаративные формы гидрокодона с контролируемым высвобождением
AU771440B2 (en) 1999-12-06 2004-03-25 Edward Mendell Co. Inc. Pharmaceutical superdisintegrant
CN1158936C (zh) * 1999-12-30 2004-07-28 Wm.雷格利Jr.公司 自口香糖中的亲脂活性剂释放
US6350480B1 (en) 1999-12-30 2002-02-26 Wm. Wrigley Jr. Company Chewing gum product including a hydrophilic gum base and method of producing
US6399101B1 (en) 2000-03-30 2002-06-04 Mova Pharmaceutical Corp. Stable thyroid hormone preparations and method of making same
AUPQ672800A0 (en) * 2000-04-06 2000-05-04 Natraherbal Pty Ltd Garlic supplement for deodoriser
WO2001091730A1 (en) 2000-05-31 2001-12-06 Drugtech Corporation Mineral supplement
US6572900B1 (en) 2000-06-09 2003-06-03 Wm. Wrigley, Jr. Company Method for making coated chewing gum products including a high-intensity sweetener
US7115288B2 (en) * 2000-06-09 2006-10-03 Wm. Wrigley Jr. Company Method for making coated chewing gum products with a coating including an aldehyde flavor and a dipeptide sweetener
US6358526B1 (en) * 2000-08-16 2002-03-19 Rexall Sundown Method of making tablets and tablet compositions produced therefrom
US6444241B1 (en) 2000-08-30 2002-09-03 Wm. Wrigley Jr. Company Caffeine coated chewing gum product and process of making
WO2002030392A2 (en) 2000-10-12 2002-04-18 Beecham Pharmaceuticals (Pte) Limited Formulation containing amoxicillin
US6756057B2 (en) 2000-10-12 2004-06-29 Beecham Pharmaceuticals (Pte) Limited Amoxicillin and potassium clavulanate dosage form
HU230875B1 (hu) 2000-10-30 2018-11-29 Euro-Celtique S.A. Szabályozott hatóanyag-leadású hidrokodon készítmények
US6887492B2 (en) 2000-12-14 2005-05-03 Leiner Health Services Corp. Magnesium plus interactive agent delivery
US6579545B2 (en) 2000-12-22 2003-06-17 Wm. Wrigley Jr. Company Coated chewing gum products containing an antigas agent
US6416752B1 (en) * 2001-01-04 2002-07-09 Whitmire Micro-Gen Research Laboratories, Inc. Termite bait composition and method
IL157634A0 (en) * 2001-03-13 2004-03-28 Penwest Pharmaceuticals Co Chronotherapeutic dosage forms containing glucocorticosteroid
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
WO2003020241A2 (en) * 2001-09-05 2003-03-13 Vectura Limited Functional powders for oral delivery
EP2957281A1 (en) 2001-09-21 2015-12-23 Egalet Ltd. Polymer release system
EP1429744A1 (en) 2001-09-21 2004-06-23 Egalet A/S Morphine polymer release system
US7101573B2 (en) * 2001-09-28 2006-09-05 Mcneil-Pcc, Inc. Simethicone solid oral dosage form
PE20030527A1 (es) 2001-10-24 2003-07-26 Gruenenthal Chemie Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen
US6753017B2 (en) * 2001-11-07 2004-06-22 Jrs Pharma Lp Process for preparing dry extracts
US20030099699A1 (en) * 2001-11-13 2003-05-29 Hanshew Dwight D. Storage stable thyroxine active drug formulations and methods for their production
US6645526B2 (en) * 2001-11-13 2003-11-11 Mylan Pharmaceuticals, Inc. Storage stable thyroxine active drug formulations and methods for their production
US7179488B2 (en) * 2001-11-29 2007-02-20 Bob Sherwood Process for co-spray drying liquid herbal extracts with dry silicified MCC
US20030206978A1 (en) * 2001-11-29 2003-11-06 Bob Sherwood Agglomerated particles including an active agent coprocessed with silicified microcrystalline cellulose
US7125563B2 (en) * 2002-04-12 2006-10-24 Dava Pharmaceuticals, Inc. Sustained release pharmaceutical preparations and methods for producing the same
US6958161B2 (en) * 2002-04-12 2005-10-25 F H Faulding & Co Limited Modified release coated drug preparation
ES2752452T3 (es) 2002-05-14 2020-04-06 Dupont Nutrition Usa Inc Composiciones de hidrocoloides de celulosa microcristalinas codesgastadas por atrición y método para su fabricación
US20040001885A1 (en) * 2002-06-27 2004-01-01 Unchalee Kositprapa Rapidly disintegrating antihistamine formulation
US20050051922A1 (en) * 2002-09-20 2005-03-10 Avinash Nangia Pharmaceutical composition with sodium lauryl sulfate as an extra-granular absorption/compression enhancer and the process to make the same
US20050020613A1 (en) * 2002-09-20 2005-01-27 Alpharma, Inc. Sustained release opioid formulations and method of use
US20040062778A1 (en) * 2002-09-26 2004-04-01 Adi Shefer Surface dissolution and/or bulk erosion controlled release compositions and devices
EP1547759A4 (en) * 2002-09-26 2013-08-28 Casematic S A De C V POLYMER BASED CASE FOR SAUSAGES
EP1562552A1 (en) * 2002-11-08 2005-08-17 Egalet A/S Controlled release carvedilol compositions
US20040161459A1 (en) * 2002-12-31 2004-08-19 Ngoc Do Fast-dissolve tablet technology
JP4989217B2 (ja) * 2003-03-26 2012-08-01 エガレット エイ／エス 薬剤物質の送達制御用マトリックス組成物
ES2360102T3 (es) * 2003-03-26 2011-05-31 Egalet A/S Sistema para la liberación controlada de morfina.
GB0310673D0 (en) 2003-05-09 2003-06-11 Givaudan Sa Alginate matrix particles
US20060165790A1 (en) * 2003-06-27 2006-07-27 Malcolm Walden Multiparticulates
WO2005027878A1 (en) * 2003-09-19 2005-03-31 Penwest Pharmaceuticals Co. Delayed released dosage forms
AU2004273958A1 (en) 2003-09-19 2005-03-31 Penwest Pharmaceuticals Co. Chronotherapeutic dosage forms
US20050196439A1 (en) * 2003-10-24 2005-09-08 J. Rettenmaier & Soehne Gmbh + Co. Kg Process for co-spray drying agents with dry silicified MCC
US8591968B2 (en) 2005-05-23 2013-11-26 Kraft Foods Global Brands Llc Edible composition including a delivery system for active components
US20050112236A1 (en) 2003-11-21 2005-05-26 Navroz Boghani Delivery system for active components as part of an edible composition having preselected tensile strength
US8591973B2 (en) 2005-05-23 2013-11-26 Kraft Foods Global Brands Llc Delivery system for active components and a material having preselected hydrophobicity as part of an edible composition
US8389031B2 (en) * 2005-05-23 2013-03-05 Kraft Foods Global Brands Llc Coated delivery system for active components as part of an edible composition
US8597703B2 (en) 2005-05-23 2013-12-03 Kraft Foods Global Brands Llc Delivery system for active components as part of an edible composition including a ratio of encapsulating material and active component
US8591972B2 (en) 2005-05-23 2013-11-26 Kraft Foods Global Brands Llc Delivery system for coated active components as part of an edible composition
US8389032B2 (en) 2005-05-23 2013-03-05 Kraft Foods Global Brands Llc Delivery system for active components as part of an edible composition having selected particle size
US7201920B2 (en) * 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
PT1566173E (pt) * 2004-02-20 2006-12-29 Udo Mattern Composição farmacêutica para aplicações orais e método para a preparar
US20050220877A1 (en) * 2004-03-31 2005-10-06 Patel Ashish A Bilayer tablet comprising an antihistamine and a decongestant
SI1765292T1 (en) 2004-06-12 2018-04-30 Collegium Pharmaceutical, Inc. Formulations of medicines to discourage abuse
GB2418854B (en) 2004-08-31 2009-12-23 Euro Celtique Sa Multiparticulates
US20060068010A1 (en) * 2004-09-30 2006-03-30 Stephen Turner Method for improving the bioavailability of orally delivered therapeutics
AU2005297923B2 (en) * 2004-10-25 2010-12-23 Japan Tobacco Inc. Solid medicinal preparation improved in solubility and stability and process for producing the same
US20070231268A1 (en) * 2004-11-24 2007-10-04 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
US20080152595A1 (en) * 2004-11-24 2008-06-26 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
US20060177380A1 (en) * 2004-11-24 2006-08-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
JP5116479B2 (ja) 2004-11-26 2013-01-09 ユーシーエル ビジネス ピーエルシー オルニチンならびにフェニルアセテートまたはフェニルブチレートを含む、肝性脳症を治療するための組成物
WO2006128471A2 (en) * 2005-06-03 2006-12-07 Egalet A/S A solid pharmaceutical composition with a first fraction of a dispersion medium and a second fraction of a matrix, the latter being at least partially first exposed to gastrointestinal fluids
NZ564789A (en) * 2005-07-22 2010-07-30 Myriad Genetics Inc High drug load formulations and dosage forms
US20070036859A1 (en) * 2005-08-11 2007-02-15 Perry Ronald L Sustained release antihistamine and decongestant composition
US7879382B2 (en) * 2005-09-30 2011-02-01 Fmc Corporation Stabilizers and compositions and products comprising same
US20100179214A1 (en) 2006-05-19 2010-07-15 Somaxon Pharmaceuticals, Inc. Doxepin trans isomers and isomeric mixtures and methods of using the same to treat sleep disorders
WO2007136741A2 (en) * 2006-05-19 2007-11-29 Somaxon Pharmaceuticals, Inc. N-desmethyl-doxepin and methods of using the same to treat sleep disorders
US20100179215A1 (en) 2006-05-19 2010-07-15 Somaxon Pharmaceuticals, Inc. Doxepin isomers and isomeric mixtures and methods of using the same to treat sleep disorders
US20080058408A1 (en) 2006-05-19 2008-03-06 Rogowski Roberta L Low-dose doxepin for treatment of sleep disorders in elderly patients
CA2687118A1 (en) * 2006-05-19 2007-12-13 Somaxon Pharmaceuticals, Inc. Methods of using low-dose doxepin for the improvement of sleep
US20070281016A1 (en) * 2006-06-06 2007-12-06 Endo Pharmaceuticals Inc., A Delaware Corporation Sustained release oxycodone composition with acrylic polymer and surfactant
US20080069891A1 (en) 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
WO2008011150A1 (en) 2006-07-20 2008-01-24 Somaxon Pharmaceuticals, Inc. Methods of improving the pharmacokinetics of doxepin
US7538652B2 (en) * 2006-08-29 2009-05-26 International Business Machines Corporation Electrical component tuned by conductive layer deletion
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
US20080081072A1 (en) * 2006-09-30 2008-04-03 Cherukuri S R Resin-complex granulation for water-soluble drugs and associated methods
US20080182890A1 (en) * 2006-10-04 2008-07-31 Somaxon Pharmaceuticals, Inc. Methods of using low-dose doxepin for the improvement of sleep
US20100105614A1 (en) 2006-10-25 2010-04-29 Somaxon Pharmaceuticals, Inc. Ultra low dose doxepin and methods of using the same to treat sleep disorders
US7998505B2 (en) * 2006-10-27 2011-08-16 Fmc Corporation Dry granulation binders, products, and use thereof
US20110077200A1 (en) 2006-12-06 2011-03-31 Somaxon Pharmaceuticals, Inc. Combination therapy using low-dose doxepin for the improvement of sleep
EP2104493A2 (en) * 2007-01-16 2009-09-30 Egalet A/S Use of i) a polyglycol and n) an active drug substance for the preparation of a pharmaceutical composition for i) mitigating the risk of alcohol induced dose dumping and/or ii) reducing the risk of drug abuse
US20090074862A1 (en) * 2007-04-13 2009-03-19 Luigi Schioppi Low-dose doxepin formulations and methods of making and using the same
WO2008134005A1 (en) * 2007-04-24 2008-11-06 Jrs Pharma Lp Co-processing of active pharmaceutical/nutraceutical ingredients
US8821928B2 (en) 2007-06-04 2014-09-02 Egalet Ltd. Controlled release pharmaceutical compositions for prolonged effect
WO2009042114A2 (en) 2007-09-21 2009-04-02 The Johns Hopkins University Phenazine derivatives and uses thereof
EP2207533B1 (en) * 2007-10-10 2021-01-06 Avantor Performance Materials, LLC Directly compressible high functionality granular microcrystalline cellulose based excipient, manufacturing process and use thereof
US20100055180A1 (en) * 2007-10-10 2010-03-04 Mallinckrodt Baker, Inc. Directly Compressible Granular Microcrystalline Cellulose Based Excipient, Manufacturing Process and Use Thereof
US20090181390A1 (en) * 2008-01-11 2009-07-16 Signosis, Inc. A California Corporation High throughput detection of micrornas and use for disease diagnosis
AU2009202778B2 (en) * 2008-07-11 2014-05-08 Commonwealth of Australia as represented by and acting through the Department of Climate Change, Energy, the Environment and Water Improved baiting method and composition
US20100094075A1 (en) * 2008-10-10 2010-04-15 Hologic Inc. Expandable medical devices with reinforced elastomeric members and methods employing the same
WO2010089132A1 (en) 2009-02-06 2010-08-12 Egalet A/S Immediate release composition resistant to abuse by intake of alcohol
CA2998344C (en) 2009-04-03 2020-06-02 Ocera Therapeutics, Inc. L-ornithine phenyl acetate and methods of making thereof
US20100285164A1 (en) * 2009-05-11 2010-11-11 Jrs Pharma Orally Disintegrating Excipient
US20120157526A1 (en) 2009-06-08 2012-06-21 Ucl Business Plc Treatment of portal hypertension and restoration of liver function using l-ornithine phenylacetate
CA2766179A1 (en) 2009-06-24 2010-12-29 Egalet Ltd. Controlled release formulations
EP3064064A1 (en) * 2009-09-30 2016-09-07 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse
US8703652B2 (en) 2009-11-06 2014-04-22 The Board Of Trustees Of The Leland Stanford Junior University Non-invasive diagnosis of graft rejection in organ transplant patients
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
WO2011143120A1 (en) 2010-05-11 2011-11-17 Cima Labs Inc. Alcoholres i stant metoprolol - containing extended - release oral dosage forms
WO2012002253A1 (ja) 2010-06-29 2012-01-05 旭化成ケミカルズ株式会社 セルロースと無機化合物を含む複合粒子
SG191288A1 (en) 2010-12-22 2013-07-31 Purdue Pharma Lp Encased tamper resistant controlled release dosage forms
PH12013501345A1 (en) 2010-12-23 2022-10-24 Purdue Pharma Lp Tamper resistant solid oral dosage forms
WO2012108864A1 (en) 2011-02-08 2012-08-16 Illumina, Inc. Selective enrichment of nucleic acids
ES2656944T3 (es) 2011-04-29 2018-03-01 Intercontinental Great Brands Llc Ácido encapsulado, método de preparación del mismo, y goma de mascar que lo comprende
US10154964B2 (en) 2011-09-07 2018-12-18 Cosmo Technologies Limited Controlled release and taste masking oral pharmaceutical composition
CA2849771A1 (en) 2011-09-22 2013-03-28 ImmuMetrix, LLC Compositions and methods for analyzing heterogeneous samples
WO2013052114A1 (en) 2011-10-05 2013-04-11 Fmc Corporation Stabilizer composition of microcrystalline cellulose and carboxymethylcellulose, method for making, and uses
CN103857739B (zh) 2011-10-05 2017-04-19 Fmc有限公司 共磨碎微晶纤维素和羧甲基纤维素的稳定剂组合物、制备方法和应用
ES2628612T3 (es) 2011-12-09 2017-08-03 Fmc Corporation Composición estabilizadora coerosionada
GB201202433D0 (en) * 2012-02-13 2012-03-28 Diurnal Ltd Controlled drug release
AU2013285988A1 (en) 2012-07-06 2015-02-12 Egalet Ltd. Abuse deterrent pharmaceutical compositions for controlled release
EP2925304B1 (en) 2012-11-30 2018-09-05 Acura Pharmaceuticals, Inc. Self-regulated release of active pharmaceutical ingredient
PE20151301A1 (es) 2013-02-05 2015-09-16 Purdue Pharma Lp Formulaciones farmaceuticas resistentes a la manipulacion indebida
EP2970958B1 (en) 2013-03-15 2017-12-06 Lineage Biosciences, Inc. Methods of sequencing the immune repertoire
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
ITBO20130126A1 (it) * 2013-03-25 2014-09-26 Naturalia Ingredients S R L Compressa comprendente fruttosio
AU2015237721B2 (en) 2014-03-26 2018-04-26 Sun Pharma Advanced Research Company Ltd. Abuse deterrent immediate release coated reservoir solid dosage form
CN107206021B (zh) 2014-11-24 2021-09-03 Ucl商业有限公司 使用降氨疗法治疗与肝星状细胞激活相关的疾病
WO2016172112A1 (en) * 2015-04-20 2016-10-27 Ocera Therapeutics, Inc. Formulations of l-ornithine phenylacetate
US10166185B2 (en) 2015-06-09 2019-01-01 J. Rettenmaier & Söhne Gmbh + Co Kg Excipient and oral solid dosage forms for oily drugs
US10835506B2 (en) 2015-08-18 2020-11-17 Ocera Therapeutics, Inc. Treatment and prevention of muscle loss using L-ornithine in combination with at least one of phenylacetate and phenylbutyrate
WO2017040607A1 (en) 2015-08-31 2017-03-09 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceutical ingredient
CN106822007B (zh) 2015-09-11 2021-12-31 西姆莱斯股份公司 口服制剂
US11219611B2 (en) 2015-11-13 2022-01-11 Ocera Therapeutics, Inc. Formulations of L-ornithine phenylacetate
US9737530B1 (en) 2016-06-23 2017-08-22 Collegium Pharmaceutical, Inc. Process of making stable abuse-deterrent oral formulations
JP7126520B2 (ja) 2017-05-11 2022-08-26 オセラ セラピューティクス， インコーポレイテッド Ｌ－オルニチンフェニルアセテートを製造する方法
JP2023506539A (ja) * 2019-12-17 2023-02-16 ９２８６－３６２０ ケベック インコーポレイテッド タンパク質／多糖コアセルベートのイン・サイチュ（ｉｎ ｓｉｔｕ）形成に基づく経口送達系
US11925707B2 (en) 2021-03-15 2024-03-12 Jrs Pharma Gmbh & Co. Kg Co-processed lubricant:MCG for tablets

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3023104A (en) * 1960-07-05 1962-02-27 American Viscose Corp Food compositions incorporating cellulose crystallite aggregates
US3067037A (en) * 1960-12-02 1962-12-04 American Viscose Corp Foamable products containing disintegrated cellulose crystallite aggregates
US3141875A (en) * 1961-03-15 1964-07-21 Fmc Corp Crystallite aggregates disintegrated in acid medium
US3573058A (en) * 1967-01-30 1971-03-30 Swift & Co Microcrystalline cellulose compositions co-dried with hydrocolloids
US3539365A (en) * 1967-02-13 1970-11-10 Fmc Corp Dispersing and stabilizing agent comprising beta-1,4 glucan and cmc and method for its preparation
US4156021A (en) * 1976-03-03 1979-05-22 Maxfibe, Inc. Oleaginous fibrous simulated food product
US4109018A (en) * 1976-05-27 1978-08-22 Thompson Jerome B Low calorie diet bread
US4143163A (en) * 1976-06-30 1979-03-06 Maxfibe, Inc. Coated fibrous cellulose product and process
AU508480B2 (en) * 1977-04-13 1980-03-20 Asahi Kasei Kogyo Kabushiki Kaisha Microcrystalline cellulose excipient and pharmaceutical composition containing thesame
US4219580A (en) * 1978-06-29 1980-08-26 Pfizer Inc. Flour substitutes
US4232052A (en) * 1979-03-12 1980-11-04 National Starch And Chemical Corporation Process for powdering high fat foodstuffs
US4664915A (en) * 1981-07-01 1987-05-12 Bristol-Myers Company Compressed and formed alkaline component suitable for use in buffered aspirin product
DK148784D0 (da) * 1984-02-29 1984-02-29 Nexus Aps Pulverprodukt
CA1261261A (en) * 1985-03-08 1989-09-26 Dev K. Mehra Coprocessed microcrystalline cellulose and calcium carbonate composition and its preparation
US4744987A (en) * 1985-03-08 1988-05-17 Fmc Corporation Coprocessed microcrystalline cellulose and calcium carbonate composition and its preparation
US4814195A (en) * 1987-03-20 1989-03-21 Winters Canning Co. Reduced calorie peanut butter product
US4786503A (en) * 1987-04-06 1988-11-22 Alza Corporation Dosage form comprising parallel lamine
US5019397A (en) * 1988-04-21 1991-05-28 Alza Corporation Aqueous emulsion for pharmaceutical dosage form
US4980193A (en) * 1988-06-17 1990-12-25 Fmx Corporation Microcrystalline cellulose-based stabilizer system for dry mix instant chocolate drink
US4911946A (en) * 1988-06-24 1990-03-27 The Nutra Sweet Company Carbohydrate cream substitute
GB8829088D0 (en) * 1988-12-13 1989-01-25 Smith Kline French Lab Compounds
US5011701A (en) * 1988-12-30 1991-04-30 Kraft General Foods, Inc. Low calorie food products having smooth, creamy, organoleptic characteristics
US5026569A (en) * 1989-01-18 1991-06-25 The Procter & Gamble Company Cotton fiber particles for use in baked goods
US5126145A (en) * 1989-04-13 1992-06-30 Upsher Smith Laboratories Inc Controlled release tablet containing water soluble medicament
KR0146720B1 (ko) * 1989-05-26 1998-08-01 챨스 씨. 펠로우스 미정질 셀룰로즈 및 갈락토만난 검을 포함하는 수성 식품용 지방-유사 증량제
EP0458484A3 (en) * 1989-05-26 1992-12-09 The Kendall Company Rubber-based adhesive tapes
DK161743C (da) * 1989-07-03 1992-02-17 Niro Atomizer As Fremgangsmaade og apparat til agglomerering af et pulverformigt materiale
US5132212A (en) * 1989-11-17 1992-07-21 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Scl gene, and a hematopoietic growth and differentiation factor encoded thereby
US5158798A (en) * 1990-02-05 1992-10-27 Pfizer Inc. Low-calorie fat substitute
US5075115A (en) * 1990-04-02 1991-12-24 Fmc Corporation Process for polymerizing poly(lactic acid)
USH1229H (en) * 1990-07-18 1993-09-07 Fmc Corporation Stabilizing agent for dry mix food products
HU206824B (en) * 1990-08-24 1993-01-28 Biogal Gyogyszergyar Process for the production of a table crystallizing in the monoclinic system, which contains light-, heat-, and moisture- sensitive active agents
DE69227240T2 (de) * 1991-01-16 1999-04-08 Fmc Corp., Philadelphia, Pa. Träger für wirkstoffe und damit hergestellte feste darreichungsformen
US5132128A (en) * 1991-04-17 1992-07-21 The J. M. Smucker Company Reduced calorie dessert topping
US5209942A (en) * 1991-11-27 1993-05-11 Thomas J. Lipton, Co., Division Of Conopco, Inc. Low fat/no fat salad dressing having mimetic functional properties fat and a process therefor
ATE196733T1 (de) * 1991-12-30 2000-10-15 Fmc Corp Zusammensetzung auf der basis von mikrokristalliner zellulose für die herstellung von kugelförmigen teilchen
EP0661934A4 (en) * 1992-09-22 1996-07-24 Fmc Corp PRODUCT AND METHOD FOR MICROCRYSTAL INCELLULOSE.
US5338562A (en) * 1992-11-25 1994-08-16 Fmc Corporation Low fat spread and process for making same
TW260612B (fi) * 1993-01-05 1995-10-21 Asahi Chemical Ind
SG45369A1 (en) * 1993-01-19 1998-10-16 Warner Lambert Co Stable oral ci-981 formulation and process of preparing same
US5366742A (en) * 1993-05-03 1994-11-22 Fmc Corporation Colloidal microcrystalline cellulose and barrier dispersant composition and method for manufacture
US5441753A (en) * 1994-01-28 1995-08-15 Fmc Corporation Coprocessed particulate bulking and formulating AIDS: their composition, production, and use
US5505982A (en) * 1994-01-28 1996-04-09 Fmc Corporation Chocolate confection
US5462761A (en) * 1994-04-04 1995-10-31 Fmc Corporation Microcrystalline cellulose and glucomannan aggregates
US5447729A (en) * 1994-04-07 1995-09-05 Pharmavene, Inc. Multilamellar drug delivery systems
US5429830A (en) * 1994-07-08 1995-07-04 Fmc Corporation Marshmallow-type confections

Also Published As

Publication number Publication date
EP0749300A4 (en) 2001-09-05
IL116674A0 (en) 1996-05-14
FI963496A7 (fi) 1996-11-06
NO963733L (no) 1996-09-06
JPH10512862A (ja) 1998-12-08
WO1996022080A1 (en) 1996-07-25
IL139728A (en) 2003-06-24
AU5019996A (en) 1996-08-07
FI963496A0 (fi) 1996-09-06
IL116674A (en) 2003-05-29
EP0749300B1 (en) 2009-10-14
IL139728A0 (en) 2002-02-10
CA2183882C (en) 2000-08-22
NO321771B1 (no) 2006-07-03
EP0749300A1 (en) 1996-12-27
NO963733D0 (no) 1996-09-06
HU9602361D0 (en) 1996-11-28
TW505529B (en) 2002-10-11
BR9605245A (pt) 1997-09-16
JP3728321B2 (ja) 2005-12-21
US5866166A (en) 1999-02-02
US5741524A (en) 1998-04-21
HUP9602361A2 (en) 1997-08-28
HUP9602361A3 (en) 2001-12-28
AU708346B2 (en) 1999-08-05
US5858412A (en) 1999-01-12
CA2183882A1 (en) 1996-07-25

Similar Documents

Publication Publication Date Title
FI963497L (fi) Farmaseuttinen täyteaine, jolla on parempi puristettavuus
FI963496L (fi) Farmaseuttinen täyteaine, jolla on parempi puristettavuus
TR199600125A2 (tr) Frenlemeli diz mafsali.
FR2717262B1 (fr) Détecteur de pression.
FI971656A7 (fi) Optokomponenttikapseli, jolla on optinen liityntä
FI960529L (fi) Antineurodegeneratiivisesti vaikuttavat 10-aminoalifatyylidibents (b,f)oksepiinit
FR2719086B1 (fr) Vérin.
NL1006015A1 (nl) Toedieninrichting.
ITBO970535A0 (it) Macchina impacchettatrice.
DK0874814T3 (da) 25-hydroxy-16-en-26,27-bishomo-cholecalciferoler
NL1002451A1 (nl) Sluitdop.
FI972912A0 (fi) Absorboiva tuote, jolla on pehmeä kavennus
TR28525A (tr) Emniyeti arttirilmis ana silindir.
ITBO970653A0 (it) Macchina bordatrice.
TR199601018A1 (tr) Farmasötik bilesikler.
FI953500L (fi) Natriummonokloriasetaatti, jolla on parannetut käyttömahdollisuudet
ES1032571Y (es) Gafa,
ES1031199Y (es) Almohada magneto-terapeutica, perfeccionada.
ES1032944Y (es) Motocicleta.
IT1280417B1 (it) Composti a struttura 3,4 diidro-2-iodometil-2,5,7,8-tetrametil-2h-1 benzopiranica.
FR2720564B1 (fr) Vérin électro-mécanique.
ES1029927Y (es) Maquina envasadora perfeccionada.
ES1028022Y (es) Cilindro de roto-friccion.
ES1030601Y (es) Radiador-convector, perfeccionado.
ES1031926Y (es) Luminaria empotrada, perfeccionada.